Bryan Kobel joined TC BioPharm in June 2021. He has been active in healthcare and life sciences for over 15 years, advising private and public companies on capital structuring and sourcing, and bringing a broad range of investors from private family capital to traditional corporate venture investors to his clients. Prior to joining TC BioPharm, Mr. Kobel was Managing Director at EF Hutton. Previously, he was Head of Healthcare/Capital Markets for The Alberleen Group. Mr. Kobel holds a BA degree from Franklin & Marshall College and held the FINRA licenses Series 7, 63, 82, 79 and 24.